FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.167,99 -625,32 (-1,05%)
ProQR Therapeutics N.V. (PRQR)
Dopo ore:
| Chiusura precedente | 1,9600 |
| Aperto | 1,9500 |
| Denaro | 1,9300 x 400 |
| Lettera | 1,9600 x 200 |
| Min-Max giorno | 1,9300 - 1,9900 |
| Intervallo di 52 settimane | 1,1100 - 3,2900 |
| Volume | |
| Media Volume | 206.503 |
| Capitalizzazione | 157,828M |
| Beta (5 anni mensile) | 0,25 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,3700 |
| Prossima data utili | 14 mag 2024 - 20 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 4,26 |
GlobeNewswireProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Daniel A. de Boer, Founder and CEO, will participate in the ADAR Editing Panel at the Chardan 7th Annual Genetic Medicines Conference in New York City. The panel is scheduled for October 2, 2023 at 9:30 am – 10:15 a
- GlobeNewswire
ProQR Therapeutics Provides Update on Ophthalmic Assets
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies today provided an update that its previously announced agreement to divest the Company’s late-stage ophthalmic assets to Laboratoires Théa S.A.S. (Théa) has been terminated. The completion of the transaction was conditional on Théa entering into employment agreements with a number of key ophthalmology
- GlobeNewswire
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Company management will participate in the HC Wainwright 25th Annual Global Investment Conference. A webcast of the Company’s presentation will be available from the “Investors & Media” section of ProQR’s website un
